Skip to content

Study · Non-randomized trial · 1978

3 results

DDAVP (1-desamino-8-D-arginine-vasopressin) treatment of central diabetes insipidus--mechanism of prolonged antidiuresis.

Seif SM, Zenser TV, Ciarochi FF, Davis BB, Robinson AG

The Journal of clinical endocrinology and metabolism1 Mar 1978Cited by 48 (Europe PMC)

PMID221517 (opens in a new tab)DOI10.1210/jcem-46-3-381 (opens in a new tab)PepBankPUB-00221517
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    All patients responded to DDAVP, with antidiuretic response durations ranging from 5-21 h.

    In plain wordsAll patients responded to DDAVP, with effects lasting 5-21 h.

    Peptide
    Desmopressin
    Outcome
    Not applicableAntidiuretic response
    Study

    n: not reported in source

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Response duration
    5 to 21 h
    DDAVP

    Source sentences

    Summary
    When DDAVP was administredd to patients, all responded, but the duration of response among patients varied from 5-21 h.
    1 context sentence
    Summary · context
    We have studied the mechanism of the prolonged antidiuretic effect by specific radioimmunossay of DDAVP in plasma of patients and by in vitro studies on the adenylate cyclase-cylic AMP system of the rat outer renal medulla.
  2. 02HumanNon-randomized trialPharmacokinetics

    In patients with central diabetes insipidus, peak plasma DDAVP occurred up to 4 h after administration.

    In plain wordsIn patients with central diabetes insipidus, blood DDAVP peaked up to 4 h after administration.

    Peptide
    Desmopressin
    Outcome
    Not applicableTime to peak plasma DDAVP
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Time to peak
    ≤ 4 h
    after administration

    Source sentences

    Summary
    The peak level of DDAVP in plasma was achieved up to 4 h after administration indicating a slow absorption from the nasal mucosa.
    1 context sentence
    Summary · context
    We have studied the mechanism of the prolonged antidiuretic effect by specific radioimmunossay of DDAVP in plasma of patients and by in vitro studies on the adenylate cyclase-cylic AMP system of the rat outer renal medulla.
  3. 03HumanNon-randomized trialPharmacokinetics

    In patients, plasma DDAVP disappearance time correlated significantly with antidiuresis duration (P less than 0.001).

    In plain wordsIn patients, the time DDAVP remained in blood correlated with how long reduced urination lasted.

    Peptide
    Desmopressin
    Outcome
    Not applicablePlasma disappearance and antidiuresis duration
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    The disappearance time of DDAVP from plasma correlated significantly with the duration of antidiuresis, P less than 0.001.
    1 context sentence
    Summary · context
    We have studied the mechanism of the prolonged antidiuretic effect by specific radioimmunossay of DDAVP in plasma of patients and by in vitro studies on the adenylate cyclase-cylic AMP system of the rat outer renal medulla.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.